Barry Flannelly
Director/Board Member chez PROTARA THERAPEUTICS, INC.
Fortune : 5 M $ au 31/03/2024
Profil
Barry P Flannelly is currently an Independent Director at Protara Therapeutics, Inc. and the Executive VP & General Manager-North America at Incyte Corp.
Previously, he served as the Chief Executive Officer at OSS Healthcare, Inc., Director at Genomic Health, Inc., VP-Global Product Strategy & Commercial Planning at Nektar Therapeutics, and Senior Vice President-Commercial at Onyx Pharmaceuticals, Inc. He also worked as a Manager-Pharmacy Services at Johns Hopkins Oncology Center.
Dr. Flannelly holds an undergraduate degree from Massachusetts College of Pharmacy & Health Science, an MBA from the University of Baltimore, and a doctorate from the University of Maryland School of Pharmacy.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INCYTE CORPORATION
0,04% | 14/02/2024 | 85 080 ( 0,04% ) | 5 M $ | 31/03/2024 |
| 07/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Barry Flannelly
| Sociétés | Poste | Début |
|---|---|---|
| INCYTE CORPORATION | Corporate Officer/Principal | 01/08/2014 |
| PROTARA THERAPEUTICS, INC. | Director/Board Member | 23/07/2020 |
Anciens postes connus de Barry Flannelly
| Sociétés | Poste | Fin |
|---|---|---|
| GENOMIC HEALTH, INC. | Director/Board Member | 08/11/2019 |
| OSS Healthcare, Inc. | Chief Executive Officer | 01/07/2014 |
| NEKTAR THERAPEUTICS | Corporate Officer/Principal | 01/04/2013 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 01/01/2011 |
| Johns Hopkins Oncology Center | Corporate Officer/Principal | - |
Formation de Barry Flannelly
| Massachusetts College of Pharmacy & Health Science | Undergraduate Degree |
| University of Baltimore | Masters Business Admin |
| University of Maryland School of Pharmacy | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| PROTARA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Genomic Health, Inc.
 Genomic Health, Inc. Medical SpecialtiesHealth Technology Genomic Health, Inc. engages in the provision of genomic-based diagnostic tests. Its tests analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. The firm uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning. The company was founded by Patrick F. Terry, Joffre B. Baker, Randal W. Scott, and Steven Shak in August 2000 and is headquartered in Redwood City, CA. | Health Technology |
| OSS Healthcare, Inc. | |
| Johns Hopkins Oncology Center |
